TCTMD’s Top 10 Most Popular Stories for March 2026

Why It Matters

The updated ACC/AHA lipid recommendations and the negative Impella trials could reshape treatment algorithms for coronary disease and heart failure, while apixaban’s bleeding advantage may shift prescribing patterns for VTE. These shifts affect drug sales, device utilization, and risk‑management strategies across cardiology.

Key Takeaways

• ACC 2026 guidelines reintroduce LDL targets, CAC, Lp(a) screening.
• Impella devices failed to improve outcomes in STEMI, high‑risk PCI.
• Apixaban shows lower bleeding risk versus rivaroxaban in VTE.
• Lp(a) and CAC independently predict 15‑year ASCVD risk.
• ORBITA‑CTO confirms PCI reduces angina in selected CTO patients.

Pulse Analysis

The ACC/AHA’s latest dyslipidemia guidance marks a decisive pivot toward aggressive, lifelong LDL management. By reinstating specific LDL targets and coupling them with mandatory coronary artery calcium and lipoprotein(a) screening, the guidelines aim to identify high‑risk patients earlier, potentially reducing atherosclerotic events before they manifest clinically. This shift not only drives demand for high‑intensity statins and PCSK9 inhibitors but also creates a market for advanced imaging and laboratory assays, prompting insurers to reevaluate coverage policies.

Concurrently, two landmark trials—STEMI Door‑to‑Unload and CHIP‑BCIS3—cast doubt on the clinical value of Impella mechanical circulatory support in both acute myocardial infarction and high‑risk percutaneous coronary intervention. The lack of mortality benefit, coupled with signals of possible harm, may temper the rapid device adoption seen over the past few years. Manufacturers are likely to intensify post‑market surveillance and explore refined patient‑selection criteria, while interventional cardiologists may revert to more conservative hemodynamic strategies pending further evidence.

On the pharmacologic front, the COBRRA editorial’s endorsement of apixaban over rivaroxaban for venous thromboembolism underscores a growing preference for agents with superior bleeding profiles. Coupled with emerging data that Lp(a) and CAC independently forecast long‑term ASCVD risk, clinicians now have a richer risk‑stratification toolkit. Meanwhile, the ORBITA‑CTO trial validates PCI’s symptom‑relief role in meticulously chosen chronic total occlusion cases, reinforcing the need for operator expertise. Together, these developments signal a nuanced, evidence‑driven evolution in cardiovascular care that will shape prescribing habits, device pipelines, and reimbursement models for years to come.